JP2024520630A5 - - Google Patents
Info
- Publication number
- JP2024520630A5 JP2024520630A5 JP2023574315A JP2023574315A JP2024520630A5 JP 2024520630 A5 JP2024520630 A5 JP 2024520630A5 JP 2023574315 A JP2023574315 A JP 2023574315A JP 2023574315 A JP2023574315 A JP 2023574315A JP 2024520630 A5 JP2024520630 A5 JP 2024520630A5
- Authority
- JP
- Japan
- Prior art keywords
- iii
- compound
- formula
- therapeutically effective
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163196843P | 2021-06-04 | 2021-06-04 | |
| US63/196,843 | 2021-06-04 | ||
| PCT/IB2022/055154 WO2022254371A1 (en) | 2021-06-04 | 2022-06-02 | Inhibitors of bruton's tyrosine kinase and methods of their use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024520630A JP2024520630A (ja) | 2024-05-24 |
| JP2024520630A5 true JP2024520630A5 (enExample) | 2025-05-28 |
Family
ID=82214195
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023574315A Pending JP2024520630A (ja) | 2021-06-04 | 2022-06-02 | ブルトン型チロシンキナーゼの阻害剤及びその使用方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230013755A1 (enExample) |
| EP (1) | EP4346834A1 (enExample) |
| JP (1) | JP2024520630A (enExample) |
| KR (1) | KR20240019214A (enExample) |
| CN (1) | CN117412753A (enExample) |
| AU (1) | AU2022284369A1 (enExample) |
| BR (1) | BR112023025459A2 (enExample) |
| CA (1) | CA3220015A1 (enExample) |
| CL (2) | CL2023003564A1 (enExample) |
| IL (1) | IL308951A (enExample) |
| JO (1) | JOP20230310A1 (enExample) |
| MX (1) | MX2023014435A (enExample) |
| TW (1) | TW202317127A (enExample) |
| WO (1) | WO2022254371A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11964976B1 (en) | 2023-09-12 | 2024-04-23 | King Faisal University | Substituted pyrido[3′,4′:4,5]pyrrolo[3,2-c][1,6]naphthyridines as CK2 inhibitors |
| WO2025228889A1 (en) | 2024-04-30 | 2025-11-06 | Boehringer Ingelheim International Gmbh | Monoarylic heterocyclic compounds as sting antagonists and the use thereof as medicament |
| WO2025228900A1 (en) | 2024-04-30 | 2025-11-06 | Boehringer Ingelheim International Gmbh | Arylamide substituted indazoles and the use thereof as medicament |
| US20250333414A1 (en) | 2024-04-30 | 2025-10-30 | Boehringer Ingelheim International Gmbh | Hetaryl substituted indazoles and benzimidazoles as sting antagonists and the use thereof as medicament |
| WO2025228899A1 (en) | 2024-04-30 | 2025-11-06 | Boehringer Ingelheim International Gmbh | Further heterocyclic compounds as sting antagonists and the use thereof as medicament |
| US20250333398A1 (en) | 2024-04-30 | 2025-10-30 | Boehringer Ingelheim International Gmbh | Monoaryl and hetaryl substituted indazoles and benzimidazoles as sting antagonists and the use thereof as medicament |
| WO2025228902A1 (en) | 2024-04-30 | 2025-11-06 | Boehringer Ingelheim International Gmbh | Heterocyclic acids as sting antagonists and the use thereof as medicament |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2887697A1 (en) | 2012-10-11 | 2014-04-17 | Pharmacyclics, Inc. | Companion diagnostics for tec family kinase inhibitor therapy |
| PL3179991T3 (pl) * | 2014-08-11 | 2022-02-14 | Acerta Pharma B.V. | Kombinacje terapeutyczne inhibitora btk i inhibitora bcl-2 |
| JO3794B1 (ar) | 2015-12-10 | 2021-01-31 | Janssen Pharmaceutica Nv | المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون |
| WO2018103060A1 (en) * | 2016-12-09 | 2018-06-14 | Janssen Pharmaceutica Nv | Inhibitors of bruton's tyrosine kinase and methods of their use |
-
2022
- 2022-06-02 AU AU2022284369A patent/AU2022284369A1/en active Pending
- 2022-06-02 EP EP22733732.6A patent/EP4346834A1/en active Pending
- 2022-06-02 WO PCT/IB2022/055154 patent/WO2022254371A1/en not_active Ceased
- 2022-06-02 US US17/830,714 patent/US20230013755A1/en active Pending
- 2022-06-02 KR KR1020247000043A patent/KR20240019214A/ko active Pending
- 2022-06-02 TW TW111120615A patent/TW202317127A/zh unknown
- 2022-06-02 CA CA3220015A patent/CA3220015A1/en active Pending
- 2022-06-02 BR BR112023025459A patent/BR112023025459A2/pt unknown
- 2022-06-02 CN CN202280039736.2A patent/CN117412753A/zh active Pending
- 2022-06-02 JP JP2023574315A patent/JP2024520630A/ja active Pending
- 2022-06-02 IL IL308951A patent/IL308951A/en unknown
- 2022-06-02 MX MX2023014435A patent/MX2023014435A/es unknown
-
2023
- 2023-11-29 CL CL2023003564A patent/CL2023003564A1/es unknown
- 2023-11-29 JO JOJO/P/2023/0310A patent/JOP20230310A1/ar unknown
-
2024
- 2024-09-26 CL CL2024002895A patent/CL2024002895A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024520630A5 (enExample) | ||
| JP2024133475A5 (enExample) | ||
| JP5661037B2 (ja) | 結核についての併用療法 | |
| JP2024133474A5 (enExample) | ||
| JP2022553954A5 (enExample) | ||
| US11065240B2 (en) | Drug combinations to treat multiple myeloma | |
| JP2023522124A5 (enExample) | ||
| EP3630101B1 (en) | Tegavivint for use in the treatment of pulmonary fibrosis | |
| KR20190109590A (ko) | 선택적인 ｂｃｌ２ 억제제를 사용하는 치료 방법 | |
| US20060079515A1 (en) | Method for the treatment of polycystic kidney disease | |
| WO2013100014A1 (ja) | 抗腫瘍剤の効果増強剤 | |
| US12599587B2 (en) | Chlorinated tetralin compounds and pharmaceutical compositions | |
| US20230241087A1 (en) | Methods Of Treating Cancer Using Prmt5 Inhibitors | |
| JP2024539872A5 (enExample) | ||
| JP2021534160A5 (enExample) | ||
| KR102904026B1 (ko) | 헤테로시클릭 단백질 키나제 억제제를 포함하는 제제 | |
| JP2023528896A5 (enExample) | ||
| JP2021530440A5 (enExample) | ||
| CN105745193B (zh) | 抗真菌氧代二氢吡啶碳酰肼衍生物 | |
| JP2024514098A5 (enExample) | ||
| JP2022554330A5 (enExample) | ||
| JP2024523558A5 (enExample) | ||
| EP1379238A1 (en) | Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer | |
| US10098860B2 (en) | Bezafibrate for the treatment of cancer | |
| JP2022509965A5 (enExample) |